bioMerieux (OTCMKTS:BMXMF) Trading Up 5.6% – Should You Buy?

bioMerieux (OTCMKTS:BMXMF)’s share price rose 5.6% during trading on Friday . The company traded as high as $87.7980 and last traded at $87.7980. Approximately 125 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 374 shares. The stock had previously closed at $83.17.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BMXMF. Piper Sandler initiated coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating for the company. Morgan Stanley downgraded shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Zacks Research downgraded shares of bioMerieux from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Finally, UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Four analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, bioMerieux currently has a consensus rating of “Reduce”.

bioMerieux Trading Up 5.6%

The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08. The company has a 50 day simple moving average of $80.50 and a 200-day simple moving average of $92.67.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.